ClinicalTrials.gg
CompletedNCT02953340Updated Mar 2, 2022Results posted

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

A Phase 3 interventional study of SPI-2012 and Pegfilgrastim in Neutropenia and Breast Cancer, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 74 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.

Enrollment
8th of 28
237 · median 121
Started
2017
with 2 others
Phase 3
11 of 33
none open now
Registered
31st of 33
by date
Lead sponsor
3 of 33
Spectrum Pharmaceuticals, Inc

Among the 33 studies testing pegfilgrastim in Neutropenia, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2017, is one of 11 in phase 3, and was the 31st registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →

About pegfilgrastim

pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing pegfilgrastim in Neutropenia as a file.
02

Study summary

The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).

Read the detailed description

This is a Phase 3, randomized, open-label, active-controlled, multicenter study to compare the efficacy and safety of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer treated with TC chemotherapy as measured by the duration of severe neutropenia (DSN).

Each cycle was 21 days. Four cycles were evaluated for this study. On Day 1 of each cycle, participants received TC chemotherapy. On Day 2 of each cycle, participants received study drug (SPI-2012 or pegfilgrastim).

After cycle 1, as applicable, participants who received at least one dose of study drug will be followed for safety for 12 months after the last dose of study treatment.

03

Conditions studied

  • Neutropenia
  • Breast Cancer

Keywords

  • Neutropenia
  • Breast Cancer
  • Long-acting Granulocyte Colony Stimulating Factor
  • Early Stage Breast Cancer
  • Docetaxel + Cyclophosphamide (TC) chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • New diagnosis of confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer
  • Candidate for or neo-adjuvant TC chemotherapy
  • (ECOG) performance status \<= 2
  • (ANC) >=1.5×10\^9/L
  • count >=100×10\^9/L
  • >9 g/dL
  • Calculated > 50 mL/min
  • Total \<=1.5 mg/dL
  • (AST) / Serum glutamic oxaloacetic transaminase (SGOT) and Alanine aminotransferase (ALT)/Serum glutamic pyruvic transaminase (SGPT) \<=2.5× (upper limit of normal)
  • Alkaline phosphatase \<=2.0×ULN

Key Exclusion Criteria:

  • Active concurrent (except non melanoma skin cancer or carcinoma in situ of the cervix) or life-threatening disease
  • Locally recurrent/ breast cancer
  • Known sensitivity to E. coli-derived products
  • Concurrent adjuvant cancer therapy
  • Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development within 12 months prior to the administration of study drug
  • Active infection, receiving anti-infectives, or any underlying medical condition that would impair ability to receive protocol treatment
  • Prior bone marrow or stem cell transplant
  • Used any drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study• Radiation therapy within 30 days prior to enrollment
  • Major surgery within 30 days prior to enrollment
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    (Arm 1): SPI-2012 and TC

    At each cycle for 4 cycles, participants received SPI-2012 at a fixed dose of 13.2 milligrams (mg)/0.6 milliliter (mL), \[3.6 mg granulocyte colony-stimulating factor {G-CSF}\] subcutaneously (SC) approximately 24-26 hours after receiving intravenous (IV) infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.

    Drug: SPI-2012 · Drug: Docetaxel · Drug: Cyclophosphamide

  • Experimental
    (Arm 2): Pegfilgrastim and TC

    At each cycle for 4 cycles, participants received pegfilgrastim 6 mg (6 mg/0.6 mL GCSF) SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.

    Drug: Pegfilgrastim · Drug: Docetaxel · Drug: Cyclophosphamide

Interventions

  • DrugEflapegrastimStudies of EflapegrastimEflapegrastim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle

    Also known as: HM10460A, Rolontis®, Eflapegrastim

  • Subcutaneous injection administered on Day 2 of each cycle.

    Also known as: Neulasta®

  • 75mg/m\^2 IV infusion administered on Day 1 of each cycle

    Also known as: Taxotere

  • 600mg/m\^2 IV infusion administered on Day 1 of each cycle

    Also known as: Cytoxan

06

What researchers measure

Primary outcomes

  1. Duration of Severe Neutropenia (DSN) in Cycle 1

    DSN was defined as the number of days of severe neutropenia (absolute neutrophil count \[ANC\] \<0.5×10\^9 per liter \[L\]) from the first occurrence of ANC below the threshold.

    Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)

Secondary outcomes

  1. Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1

    Time to ANC recovery was defined as the time from chemotherapy administration until the participants ANC increased to \>=1.5×10\^9/L after the expected nadir. For participants with ANC value \>=1.5×10\^9/L at all times, time to ANC Recovery was assigned a value of 0.

    Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)

  2. Depth of ANC Nadir in Cycle 1

    The depth of ANC Nadir was defined as the lowest ANC value after administration of study drug (SPI-2012 or pegfilgrastim) in Cycle 1.

    Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)

  3. Number of Participants With Febrile Neutropenia (FN) in Cycle 1

    FN was defined as an oral temperature \>38.3 degree Celsius (°C) (101.0 degrees Fahrenheit \[°F\]) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.

    Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)

  4. Duration of Severe Neutropenia (DSN) in Cycles 2, 3 and 4

    DSN was defined as the number of days of severe neutropenia (ANC \<0.5×10\^9/L) from the first occurrence of ANC below the threshold.

    Time frame: Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle = 21 days)

  5. Number of Participants With Neutropenic Complications in Cycle 1

    Neutropenic complications refer to hospitalizations due to neutropenic events and/or the use of anti-infectives due to neutropenia.

    Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)

  6. Number of Participants With Febrile Neutropenia in Cycles 2, 3 and 4

    FN was defined as an oral temperature \>38.3°C (101.0°F) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.

    Time frame: Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle = 21 days)

  7. Relative Dose Intensity (RDI) of TC Chemotherapy

    RDI was defined as the percentage of the planned dose of TC chemotherapy that each participant actually received during the study, and is expressed as the total dose received, divided by total dose planned multiplied by 100. The planned dose was defined as the dose that would be given if no doses were missed and/or no dose reductions were made for the number of cycles started. The total planned dose was the sum of planned doses over all cycles.

    Time frame: Cycles 1, 2, 3 and 4 (each cycle = 21 days)

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and Death

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product or study procedure, whether or not considered related to the medicinal product. A TEAE is any AE that occurred from the first dose of study treatment through 12 months after the last dose of study treatment or 35 (±5) days after date of participant early discontinuation. SAE is defined as any AE which meets any of the following criteria: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, includes important medical events.

    Time frame: Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months)

  9. Number of Participants With Clinically Significant Laboratory Abnormalities

    The number of participants with clinically significant hematology (including basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils, neutrophils/leukocytes, platelets, and white blood cells) and serum chemistry (including alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin, calcium, cholesterol, creatinine, potassium, sodium, and triglycerides) laboratory abnormalities were reported. Clinically significant findings in laboratory parameters were based on investigator's discretion according to Common Technical Criteria for Adverse Events (CTCAE) Version 4.03.

    Time frame: Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months)

07

Results

Posted Mar 2, 2022

Participant flow

This study was conducted at 74 sites in the United States, Canada, Hungary, Poland, India, Korea from 10 May 2017 to 06 May 2019. The study was conducted in two periods: treatment period (first dose of TC until 35 (± 5) days after last dose of treatment) and safety follow-up period (End of Treatment Visit through 12 months after last dose of study treatment).

Participant flow — Overall Study
Milestone(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Started118119
Safety population117118
Entered safety follow-up period117118
Completed9685
Not completed2234
Withdrew: Death01
Withdrew: Investigator decision33
Withdrew: Initiated non-protocol therapy514
Withdrew: Myeloid growth factors treatment01
Withdrew: Withdrawal by subject99
Withdrew: Sponsor decision02
Withdrew: Lost to follow-up32
Withdrew: Reason not specified22

Outcome measures

PrimaryDuration of Severe Neutropenia (DSN) in Cycle 1

DSN was defined as the number of days of severe neutropenia (absolute neutrophil count \[ANC\] \<0.5×10\^9 per liter \[L\]) from the first occurrence of ANC below the threshold.

Time frame:
Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Reported as:
Mean · Days
Duration of Severe Neutropenia (DSN) in Cycle 1
Days(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Duration of Severe Neutropenia (DSN) in Cycle 10.31 ± 0.6880.39 ± 0.949
Statistical analysis
  • (Arm 1): SPI-2012 and TC vs (Arm 2): Pegfilgrastim and TC · t-statistics · p = < 0.0001 · Mean difference: -0.074 · 95% CI -0.292 to 0.129The p-values are based on the calculated t-statistics from the bootstrapped sample mean and standard deviation.
SecondaryTime to Absolute Neutrophil Count (ANC) Recovery in Cycle 1

Time to ANC recovery was defined as the time from chemotherapy administration until the participants ANC increased to \>=1.5×10\^9/L after the expected nadir. For participants with ANC value \>=1.5×10\^9/L at all times, time to ANC Recovery was assigned a value of 0.

Time frame:
Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Reported as:
Mean · Days
Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1
Days(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 13.49 ± 3.7233.35 ± 3.745
SecondaryDepth of ANC Nadir in Cycle 1

The depth of ANC Nadir was defined as the lowest ANC value after administration of study drug (SPI-2012 or pegfilgrastim) in Cycle 1.

Time frame:
Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Reported as:
Mean · 10^9 cells/L
Depth of ANC Nadir in Cycle 1
10^9 cells/L(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Depth of ANC Nadir in Cycle 12.67 ± 3.5042.06 ± 2.034
SecondaryNumber of Participants With Febrile Neutropenia (FN) in Cycle 1

FN was defined as an oral temperature \>38.3 degree Celsius (°C) (101.0 degrees Fahrenheit \[°F\]) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.

Time frame:
Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Febrile Neutropenia (FN) in Cycle 1
Participants(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Number of Participants With Febrile Neutropenia (FN) in Cycle 114
SecondaryDuration of Severe Neutropenia (DSN) in Cycles 2, 3 and 4

DSN was defined as the number of days of severe neutropenia (ANC \<0.5×10\^9/L) from the first occurrence of ANC below the threshold.

Time frame:
Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle = 21 days)
Reported as:
Mean · Days
Duration of Severe Neutropenia (DSN) in Cycles 2, 3 and 4
Days(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Cycle 20.08 ± 0.2670.09 ± 0.432
Cycle 30.07 ± 0.2520.07 ± 0.283
Cycle 40.07 ± 0.2520.08 ± 0.266
SecondaryNumber of Participants With Neutropenic Complications in Cycle 1

Neutropenic complications refer to hospitalizations due to neutropenic events and/or the use of anti-infectives due to neutropenia.

Time frame:
Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Neutropenic Complications in Cycle 1
Participants(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Number of Participants With Neutropenic Complications in Cycle 115
SecondaryNumber of Participants With Febrile Neutropenia in Cycles 2, 3 and 4

FN was defined as an oral temperature \>38.3°C (101.0°F) or two consecutive readings of \>38.0°C (100.4°F) for 2 hours and ANC \<1.0×10\^9/L.

Time frame:
Days 1, 4, 7, 10, and 15 of Cycles 2, 3, and 4 (each cycle = 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Febrile Neutropenia in Cycles 2, 3 and 4
Participants(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Cycle 202
Cycle 300
Cycle 400
SecondaryRelative Dose Intensity (RDI) of TC Chemotherapy

RDI was defined as the percentage of the planned dose of TC chemotherapy that each participant actually received during the study, and is expressed as the total dose received, divided by total dose planned multiplied by 100. The planned dose was defined as the dose that would be given if no doses were missed and/or no dose reductions were made for the number of cycles started. The total planned dose was the sum of planned doses over all cycles.

Time frame:
Cycles 1, 2, 3 and 4 (each cycle = 21 days)
Reported as:
Mean · Percentage of planned dose
Relative Dose Intensity (RDI) of TC Chemotherapy
Percentage of planned dose(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Docetaxel96.9 ± 7.7098.4 ± 7.89
Cyclophosphamide98.4 ± 5.2798.8 ± 6.40
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and Death

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product or study procedure, whether or not considered related to the medicinal product. A TEAE is any AE that occurred from the first dose of study treatment through 12 months after the last dose of study treatment or 35 (±5) days after date of participant early discontinuation. SAE is defined as any AE which meets any of the following criteria: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, includes important medical events.

Time frame:
Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and Death
Participants(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC(Arm 1): SPI-2012 and TC: Follow-up PeriodArm 2: Pegfilgrastim and TC: Follow-up Period
TEAEs1151163348
SAEs121924
Death0100
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities

The number of participants with clinically significant hematology (including basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils, neutrophils/leukocytes, platelets, and white blood cells) and serum chemistry (including alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], aspartate aminotransferase \[AST\], bilirubin, calcium, cholesterol, creatinine, potassium, sodium, and triglycerides) laboratory abnormalities were reported. Clinically significant findings in laboratory parameters were based on investigator's discretion according to Common Technical Criteria for Adverse Events (CTCAE) Version 4.03.

Time frame:
Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities
Participants(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC
Hematology: Basophils00
Hematology: Basophils/Leukocytes00
Hematology: Eosinophils00
Hematology: Eosinophils/Leukocytes00
Hematology: Hematocrit42
Hematology: Hemoglobin64
Hematology: Lymphocytes00
Hematology: Lymphocytes/Leukocytes613
Hematology: Monocytes00
Hematology: Monocytes/Leukocytes00
Hematology: Neutrophils1723
Hematology: Neutrophils/Leukocytes129
Hematology: Platelets102
Hematology: White Blood Cells1618
Chemistry: Alanine aminotransferase21
Chemistry: Alkaline phosphatase01
Chemistry: Aspartate aminotransferase11
Chemistry: Bilirubin00
Chemistry: Calcium11
Chemistry: Cholesterol00
Chemistry: Creatinine00
Chemistry: Potassium01
Chemistry: Sodium02
Chemistry: Triglycerides00

Adverse events

Collected over Up to 4 cycles (each cycle = 21 days) plus a 12-month follow-up from the last dose (up to 15 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
(Arm 1): SPI-2012 and TC0/117 (0%)12/117 (10.3%)115/117 (98.3%)
(Arm 2): Pegfilgrastim and TC1/118 (0.8%)19/118 (16.1%)116/118 (98.3%)
(Arm 1): SPI-2012 and TC: Follow-up Period0/117 (0%)2/117 (1.7%)33/117 (28.2%)
(Arm 2): Pegfilgrastim and TC: Follow-up Period0/118 (0%)4/118 (3.4%)48/118 (40.7%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
Event(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC(Arm 1): SPI-2012 and TC: Follow-up Period(Arm 2): Pegfilgrastim and TC: Follow-up Period
NeutropeniaBlood and lymphatic system disorders0/1173/1180/1170/118
FallInjury, poisoning and procedural complications2/1170/1180/1170/118
Febrile neutropeniaBlood and lymphatic system disorders0/1172/1180/1170/118
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1172/1180/1170/118
PneumoniaInfections and infestations0/1172/1180/1170/118
Chest painGeneral disorders1/1171/1180/1170/118
PyrexiaGeneral disorders1/1171/1180/1170/118
Supraventricular tachycardiaCardiac disorders1/1170/1180/1170/118
Cardiac arrestCardiac disorders0/1170/1181/1170/118
Myocardial infarctionCardiac disorders0/1170/1181/1170/118
Most frequent other events
Showing 10 of 56
Most frequent other events
Event(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TC(Arm 1): SPI-2012 and TC: Follow-up Period(Arm 2): Pegfilgrastim and TC: Follow-up Period
NauseaGastrointestinal disorders50/11761/1181/1171/118
Lymphocyte count decreasedInvestigations44/11754/1180/1171/118
FatigueGeneral disorders40/11751/1180/1170/118
Bone painMusculoskeletal and connective tissue disorders47/11751/1181/1171/118
AlopeciaSkin and subcutaneous tissue disorders40/11743/1181/1170/118
DiarrhoeaGastrointestinal disorders38/11740/1181/1173/118
NeutropeniaBlood and lymphatic system disorders37/11737/1180/1170/118
HeadacheNervous system disorders31/11735/1180/1171/118
White blood cell count decreasedInvestigations22/11731/1181/1172/118
ConstipationGastrointestinal disorders26/11724/1180/1172/118

Baseline characteristics

Intent-to-Treat (ITT) Population includes all participants who were randomized.

Age, Continuous
Age, Continuous(years)(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TCTotal
Mean57.9 ± 11.2758.1 ± 12.6758.0 ± 11.97
Sex: Female, Male
Sex: Female, Male(Participants)(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TCTotal
Female118119237
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TCTotal
Hispanic or Latino181533
Not Hispanic or Latino100104204
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)(Arm 1): SPI-2012 and TC(Arm 2): Pegfilgrastim and TCTotal
White or Caucasian8596181
Black or African American11718
Asian201636
American Indian or Alaska Native101
Other101
08

Study locations

74 sites
  • ACRC/ Arizona Clinical Research Center Inc.
    Tucson, Arizona 85715, United States
  • Yuma Regional Cancer Center
    Yuma, Arizona 85364, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • NEA Baptist Clinic | Fowler Family Center for Cancer Care
    Jonesboro, Arkansas 72401, United States
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Compassionate Care Research Group, Inc.
    Fountain Valley, California 92708, United States
  • California Cancer Associates for Research and Excellence Inc.
    Fresno, California 93720, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Los Angeles Hematology Oncology Medical Group
    Los Angeles, California 90017, United States
  • Desert Regional Medical Center
    Palm Springs, California 92262, United States
  • Emad Ibrahim, MD, INC.
    Redlands, California 92373, United States
  • Innovative Clinical Research Institute/ The Oncology Institute of Hope and Innovation
    Whittier, California 90603, United States
  • Denver Health & Hospital Authority
    Denver, Colorado 80204, United States
  • Pasco Pinellas Cancer Center
    Holiday, Florida 34691, United States
  • Lakes Research, LLC
    Miami Lakes, Florida 33014, United States
  • Mid-Florida Hematology and Oncology Centers
    Orange City, Florida 32763, United States
  • Millennium Oncology
    Pembroke Pines, Florida 33024, United States
  • BRCR Medical Center Inc
    Plantation, Florida 33324, United States
  • Pinellas Hematology and Oncology
    Saint Petersburg, Florida 33709, United States
  • Bond & Steele Clinic, PA.
    Winter Haven, Florida 33880, United States
  • John B. Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Cancer Center of Middle Georgia
    Dublin, Georgia 31021, United States
  • Dwight D. Eisenhower Army Medical Center
    Fort Gordon, Georgia 30905, United States
  • Saint Alphonsus Regional Medical Center
    Boise, Idaho 83706, United States
  • Oncology Specialists, SC
    Park Ridge, Illinois 60068, United States
  • FPN Oncology and Hematology Specialists
    Indianapolis, Indiana 46237, United States
  • Commonwealth Hematology-Oncology, PSC
    Danville, Kentucky 40422, United States
  • Pontchartrain Cancer Center
    Covington, Louisiana 70433, United States
  • Quest Research Institute
    Royal Oak, Michigan 48073, United States
  • Coborn Cancer Center
    Saint Cloud, Minnesota 56303, United States
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401, United States
  • Freeman Health Systems
    Joplin, Missouri 64804, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • CHI Health St Francis, St Francis Cancer Treatment Center
    Grand Island, Nebraska 68803, United States
  • Waverly Hematology Oncology
    Cary, North Carolina 27518, United States
  • Gaston Hematology & Oncology Associates, PC
    Gastonia, North Carolina 28054, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • The Christ Hospital Cancer Center
    Cincinnati, Ohio 45219, United States
  • St. Elizabeth Youngstown Hospital JACBCC/Oncology/ Mercy Health Youngstown LLC
    Youngstown, Ohio 44501, United States
  • Carolina Blood and Cancer Care Associates
    Rock Hill, South Carolina 29732, United States
  • The West Clinic, PC, d/b/a West Cancer Center
    Germantown, Tennessee 38138, United States
  • CHI St Joseph Health Cancer Center
    Bryan, Texas 77802, United States
  • Envision Cancer Center, LLC
    Laredo, Texas 78041, United States
  • Texas Oncology, PA- McAllen South 2nd Street
    McAllen, Texas 78503, United States
  • HOPE Cancer Center of East Texas
    Tyler, Texas 75701, United States
  • Delta Hematology/Oncology Associates
    Portsmouth, Virginia 23704, United States
  • Providence Regional Center Partnership
    Everett, Washington 98201, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • CISSS de la Montérégie-Centre
    Longueuil, Quebec J4V 2H1, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Magyar Honvedseg Egeszsegugyi Kozpont, Onkologiai Osztaly
    Budapest, 1062, Hungary
  • Szent Imre Egyetemi Oktatokorhaz, Klinikai Onkologiai Osztaly
    Budapest, 1115, Hungary
  • Orszagos Onkologiai Intezet, ""B"" Belgyogyaszati Onkologiai Osztaly
    Budapest, 1122, Hungary
  • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Okato Korhaz, Klinikai Onkologiai es Sugarterapias Centrum
    Miskolc, 3526, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak, Egyetemi Oktato Korhaz, Onkoradiologiai Osztaly
    Nyíregyháza, 4400, Hungary
  • Tolna Megyei Balassa Janos Korhaz, Klinikai Onkologiai Osztaly
    Szekszard, 7100, Hungary
  • KEM Hospital Research Centre
    Pune, Maharashtra 411011, India
  • Christian Medical College
    Vellore, Tamil Nadu 632004, India
  • Samsung Medical Center
    Irwon-ro, Gangnam-gu Seoul 06351, Korea, Republic of
  • Wonju Severance Christian Hospital
    Ilsan-ro, Gangwon-do 26426, Korea, Republic of
  • National Cancer Center
    IIsan-ro, Gyeonggi-do 10408, Korea, Republic of
  • Cha Bundang Medical Center
    Yatap-ro, Gyeonggi-do 13496, Korea, Republic of
  • Seoul National University Hospital
    Daehwa-ro, Jongno-gu Seoul 03080, Korea, Republic of
  • Inha University Hospital
    Inhang-ro, Jung-guIncheon 22332, Korea, Republic of
  • Korea University Anam Hospital
    Inchon-ro, Seongbuk-guSeoul 02841, Korea, Republic of
  • Severance Hospital
    Yonsei-ro, Seoul 03722, Korea, Republic of
  • BIALOSTOCKIE CENTRUM ONKOLOGII im. Marii Sklodowskiej-Curie Oddzial Onkologii Klinicznej im. Ewy Pileckiej z Pododdzialem Chemioterapii dziennej
    Bialystok, 15-027, Poland
  • Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego Oddział Onkologii Klinicznej
    Grudziadz, 86-300, Poland
  • Instytut Centrum Zdrowia Matki Polki Klinika Chirurgii Onkologicznej i Chorob Piersi z Pododdzialem Onkologii Klinicznej
    Lodz, 93-338, Poland
  • Pracownia Leku Cytotoksycznego Szpitala Klinicznego Przemienienia Panskiego UM im. Karola Marcinkowskiego w Poznaniu
    Poznan, 60-569, Poland
  • Szpital Rejonowy im. Dr. Jozefa Rostka w Raciborzu Dzienny Oddzial Chemioterapii
    Racibórz, 47-400, Poland
  • MrukMed. Lekarz Beata Madej Mruk i Partner. Spolka Partnerska Oddzial nr 1 w Rzeszowie
    Rzeszow, 35-021, Poland
  • Zachodniopomorskie Centrum Onkologii Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych
    Szczecin, 71-730, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jun 2018, 12 months.

Results were first posted in Mar 2022, 3 years 8 months after primary completion. A results delay was requested in Jan 2020.

Of 16 phase 3 interventional studies under Neutropenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2016
First posted
Nov 2, 2016
StartActual
May 10, 2017
Primary completionActual
Jun 8, 2018
CompletionActual
May 6, 2019
Results delay requested
Jan 23, 2020
Results first posted
Mar 2, 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02953340
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
May 10, 2017
Primary completion
Jun 8, 2018
Completion
May 6, 2019
Results posted
Mar 2, 2022
Last update
Mar 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eflapegrastim · Pegfilgrastim

Start the discussion